For Immediate Release: May 23, 2023
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
Every September the Recovery Month Campaign aims to increase awareness and understanding of mental and substance use disorders and celebrate the people who recover.
Over the years, Recovery Month has promoted and supported new evidence...
The Substance Abuse and Mental Health Services Administration (SAMHSA) National Center of Excellence for Tobacco-Free Recovery Grant is now open for applications. Offering up to 5 million USD the grant can be used for a range of projects...
